Nano-multilamellar lipid vesicles (NMVs) enhance protective antibody responses against Shiga toxin (Stx2a) produced by enterohemorrhagic Escherichia coli strains (EHEC)

Autor(es)

Rodrigues-Jesus, M. J. ^[1] ; Fotoran, W. L. ^[2] ; Cardoso, R. M. ^[3] ; Araki, K. ^[3] ; Wunderlich, G. ^[2] ; Ferreira, Luis C. S. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Vaccine Dev Lab, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Unit Drug Dev & Plasmodium Mol Biol, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Inst Chem, Dept Fundamental Chem, Supramol Chem & Nanotechnol Lab, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Brazilian Journal of Microbiology; v. 50, n. 1, p. 67-77, JAN 2019.
• Citações Web of Science: 1

Resumo

Microlipid vesicles (MLV) have a broad spectrum of applications for the delivery of molecules, ranging from chemical compounds to proteins, in both in vitro and in vivo conditions. In the present study, we developed a new set of nanosize multilayer lipid vesicles (NMVs) containing a unique combination of lipids. The NMVs enable the adsorption of histidine-tagged proteins at the vesicle surface and were demonstrated to be suitable for the in vivo delivery of antigens. The NMVs contained a combination of neutral (DOPC) and anionic (DPPG) lipids in the inner membrane and an external layer composed of DOPC, cholesterol, and a nickel-containing lipid (DGS-NTA {[}Ni]). NMVs combined with a recombinant form of the B subunit of the Shiga toxin (rStx2B) produced by certain enterohemorragic Escherichia coli (EHEC) strains enhanced the immunogenicity of the antigen after parenteral administration to mice. Mice immunized with rStx2B-loaded NMVs elicited serum antibodies capable of neutralizing the toxic activities of the native toxin; this result was demonstrated both in vitro and in vivo. Taken together, these results demonstrated that the proposed NMVs represent an alternative for the delivery of antigens, including recombinant proteins, generated in different expression systems. (AU)

• Processo FAPESP: 14/21141-4 - Desenvolvimento de uma estratégia vacinal contra a toxina de Shiga de Escherichia coli enterohemorrágica (EHEC) baseada na proteína recombinante Stx2AB incorporada a lipossomas
• Beneficiário: Mônica Josiane Rodrigues de Jesus
• Linha de fomento: Bolsas no Brasil - Mestrado
• Processo FAPESP: 15/17174-7 - Avaliação de fatores que influem na expressão de famílias multigênicas var, rif e surf de P. falciparum, o parasita da malária humana
• Beneficiário: Gerhard Wunderlich
• Linha de fomento: Auxílio à Pesquisa - Regular